Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Department of Urology, Mayo Clinic, Rochester, NY, USA.
Eur Urol. 2021 Nov;80(5):575-588. doi: 10.1016/j.eururo.2021.01.021. Epub 2021 Feb 6.
With the addition of active surveillance and thermal ablation (TA) to the urologist's established repertoire of partial (PN) and radical nephrectomy (RN) as first-line management options for localized renal cell carcinoma (RCC), appropriate treatment decision-making has become increasingly nuanced.
To critically review the treatment options for localized, nonrecurrent RCC; to highlight the patient, renal function, tumor, and provider factors that influence treatment decisions; and to provide a framework to conceptualize that decision-making process.
A collaborative critical review of the medical literature was conducted.
We identify three key decision points when managing localized RCC: (1) decision for surveillance versus treatment, (2) decision regarding treatment modality (TA, PN, or RN), and (3) decision on surgical approach (open vs minimally invasive). In evaluating factors that influence these treatment decisions, we elaborate on patient, renal function, tumor, and provider factors that either directly or indirectly impact each decision point. As current nomograms, based on preselected patient datasets, perform poorly in prospective settings, these tools should be used with caution. Patient decision aids are an underutilized tool in decision-making.
Localized RCC requires highly nuanced treatment decision-making, balancing patient- and tumor-specific clinical variables against indirect structural influences to provide optimal patient care.
With expanding treatment options for localized kidney cancer, treatment decision is highly nuanced and requires shared decision-making. Patient decision aids may be helpful in the treatment discussion.
随着主动监测和热消融(TA)的加入,泌尿科医生将部分(PN)和根治性肾切除术(RN)作为局限性肾细胞癌(RCC)的一线治疗选择,适当的治疗决策变得越来越复杂。
批判性地回顾局限性、非复发性 RCC 的治疗选择;强调影响治疗决策的患者、肾功能、肿瘤和提供者因素;并提供一个概念化决策过程的框架。
对医学文献进行了合作的批判性回顾。
我们确定了管理局限性 RCC 的三个关键决策点:(1)监测与治疗的决策,(2)治疗方式(TA、PN 或 RN)的决策,(3)手术方法(开放与微创)的决策。在评估影响这些治疗决策的因素时,我们详细阐述了直接或间接影响每个决策点的患者、肾功能、肿瘤和提供者因素。由于当前基于预选患者数据集的列线图在前瞻性环境中的表现不佳,因此应谨慎使用这些工具。患者决策辅助工具在决策制定中未得到充分利用。
局限性 RCC 需要高度复杂的治疗决策,需要平衡患者和肿瘤特定的临床变量与间接结构影响,以提供最佳的患者护理。
随着局限性肾癌治疗选择的扩大,治疗决策非常复杂,需要共同决策。患者决策辅助工具可能有助于治疗讨论。